LEGEND BIOTECH CORP-ADR (LEGN) Fundamental Analysis & Valuation

NASDAQ:LEGN • US52490G1022

Current stock price

19.14 USD
+0.09 (+0.47%)
At close:
19.14 USD
0 (0%)
After Hours:

This LEGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. LEGN Profitability Analysis

1.1 Basic Checks

  • LEGN had negative earnings in the past year.
  • LEGN had a negative operating cash flow in the past year.
  • In the past 5 years LEGN always reported negative net income.
  • In the past 5 years LEGN always reported negative operating cash flow.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of LEGN (-17.12%) is better than 77.95% of its industry peers.
  • With a decent Return On Equity value of -29.62%, LEGN is doing good in the industry, outperforming 75.82% of the companies in the same industry.
Industry RankSector Rank
ROA -17.12%
ROE -29.62%
ROIC N/A
ROA(3y)-18.58%
ROA(5y)-25.07%
ROE(3y)-29.35%
ROE(5y)-40.14%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • LEGN has a better Gross Margin (60.34%) than 77.56% of its industry peers.
  • In the last couple of years the Gross Margin of LEGN has grown nicely.
  • LEGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.01%
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LEGN Health Analysis

2.1 Basic Checks

  • LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LEGN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, LEGN has more shares outstanding
  • The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.45 indicates that LEGN is not in any danger for bankruptcy at the moment.
  • LEGN's Altman-Z score of 4.45 is fine compared to the rest of the industry. LEGN outperforms 72.15% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that LEGN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.09, LEGN is not doing good in the industry: 61.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 4.45
ROIC/WACCN/A
WACC9.1%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 1.96 indicates that LEGN should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.96, LEGN is doing worse than 77.56% of the companies in the same industry.
  • LEGN has a Quick Ratio of 1.91. This is a normal value and indicates that LEGN is financially healthy and should not expect problems in meeting its short term obligations.
  • LEGN's Quick ratio of 1.91 is on the low side compared to the rest of the industry. LEGN is outperformed by 76.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.91
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LEGN Growth Analysis

3.1 Past

  • The earnings per share for LEGN have decreased strongly by -68.42% in the last year.
  • The Revenue has grown by 64.04% in the past year. This is a very strong growth!
  • Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 68.83% on average per year.
EPS 1Y (TTM)-68.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-206.67%
Revenue 1Y (TTM)64.04%
Revenue growth 3Y106.41%
Revenue growth 5Y68.83%
Sales Q2Q%64.22%

3.2 Future

  • LEGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.59% yearly.
  • Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 20.63% on average per year.
EPS Next Y121.03%
EPS Next 2Y67.8%
EPS Next 3Y43.22%
EPS Next 5Y32.59%
Revenue Next Year40.49%
Revenue Next 2Y36.57%
Revenue Next 3Y31%
Revenue Next 5Y20.63%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. LEGN Valuation Analysis

4.1 Price/Earnings Ratio

  • LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 56.87, LEGN can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, LEGN is valued cheaper than 89.56% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, LEGN is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 56.87
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as LEGN's earnings are expected to grow with 43.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.8%
EPS Next 3Y43.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LEGN Dividend Analysis

5.1 Amount

  • No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEGN Fundamentals: All Metrics, Ratios and Statistics

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (4/2/2026, 8:00:03 PM)

After market: 19.14 0 (0%)

19.14

+0.09 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-11
Inst Owners50.35%
Inst Owner Change4.15%
Ins Owners0.08%
Ins Owner Change-1.77%
Market Cap3.51B
Revenue(TTM)1.03B
Net Income(TTM)-296.80M
Analysts83.33
Price Target65.48 (242.11%)
Short Float %19.87%
Short Ratio8.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-99.96%
Min EPS beat(2)-155.43%
Max EPS beat(2)-44.48%
EPS beat(4)0
Avg EPS beat(4)-175.88%
Min EPS beat(4)-366.2%
Max EPS beat(4)-44.48%
EPS beat(8)2
Avg EPS beat(8)-68.73%
EPS beat(12)4
Avg EPS beat(12)-49.03%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.08%
Min Revenue beat(2)-2.14%
Max Revenue beat(2)-2.02%
Revenue beat(4)1
Avg Revenue beat(4)0.95%
Min Revenue beat(4)-2.14%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)2.5%
Revenue beat(12)5
Avg Revenue beat(12)2.34%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.49%
PT rev (3m)-8.81%
EPS NQ rev (1m)78.1%
EPS NQ rev (3m)70.22%
EPS NY rev (1m)-11.2%
EPS NY rev (3m)-23.11%
Revenue NQ rev (1m)-0.68%
Revenue NQ rev (3m)-6.34%
Revenue NY rev (1m)-2.31%
Revenue NY rev (3m)-5.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 56.87
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB 3.5
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)0.34
Fwd EY1.76%
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS5.61
BVpS5.46
TBVpS5.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.12%
ROE -29.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.34%
FCFM N/A
ROA(3y)-18.58%
ROA(5y)-25.07%
ROE(3y)-29.35%
ROE(5y)-40.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.01%
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 98.96%
Cap/Sales 2.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.91
Altman-Z 4.45
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)90.15%
Cap/Depr(5y)146.1%
Cap/Sales(3y)4.33%
Cap/Sales(5y)20.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-206.67%
EPS Next Y121.03%
EPS Next 2Y67.8%
EPS Next 3Y43.22%
EPS Next 5Y32.59%
Revenue 1Y (TTM)64.04%
Revenue growth 3Y106.41%
Revenue growth 5Y68.83%
Sales Q2Q%64.22%
Revenue Next Year40.49%
Revenue Next 2Y36.57%
Revenue Next 3Y31%
Revenue Next 5Y20.63%
EBIT growth 1Y55.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year222.11%
EBIT Next 3Y78.29%
EBIT Next 5Y52.92%
FCF growth 1Y18.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.43%
OCF growth 3YN/A
OCF growth 5YN/A

LEGEND BIOTECH CORP-ADR / LEGN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LEGN.


Can you provide the valuation status for LEGEND BIOTECH CORP-ADR?

ChartMill assigns a valuation rating of 3 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.


What is the profitability of LEGN stock?

LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.


How financially healthy is LEGEND BIOTECH CORP-ADR?

The financial health rating of LEGEND BIOTECH CORP-ADR (LEGN) is 3 / 10.


What is the earnings growth outlook for LEGEND BIOTECH CORP-ADR?

The Earnings per Share (EPS) of LEGEND BIOTECH CORP-ADR (LEGN) is expected to grow by 121.03% in the next year.